Obesity Alters Psoriasis Severity and Biologic Response, Review Finds

Patients with psoriasis do not only have inflamed skin—many are also carrying inflamed fat that feeds the same disease and reshapes how well systemic therapies work, according to a review published online in the Journal of Clinical Medicine.¹ Obesity is not simply a comorbidity, the review argues: it independently worsens severity, blunts biologic drug survival, and should factor into treatment choice.

A Bidirectional, Inflammation-Driven Relationship

Adipose tissue functions as an active immuno-endocrine organ rather than a passive energy store. In obesity, hypertrophied fat cells turn hypoxic and draw in macrophages, driving chronic low-grade inflammation and skewing adipokine production: leptin, which promotes T-helper 17 (Th17) differentiation and keratinocyte proliferation, rises, while adiponectin, an anti-inflammatory adipokine that correlates inversely with Psoriasis Area and Severity Index (PASI) scores, falls. That environment activates the interleukin (IL)-23/Th17 axis central to psoriasis pathogenesis, and meta-analyses show obese individuals carry an approximately 1.5- to 2-fold higher risk of developing psoriasis than normal-weight individuals, with central adiposity predicting risk even more strongly than body mass index (BMI) alone.

The overlap is substantial: a separate global meta-analysis found psoriasis and obesity co-occur in 25% of patients overall and 35% of adults, rising alongside disease severity.² Obese patients with psoriasis also carried a higher burden of psoriatic arthritis, hypertension, dyslipidemia, insulin resistance, and nonalcoholic fatty liver disease than non-obese patients, the review noted.¹

A Narrative Synthesis Built on Randomized and Real-World Data

The review synthesized epidemiological studies, mechanistic research, randomized trials, and real-world registry data on the psoriasis-obesity relationship rather than presenting a single new dataset. Evidence spanned small, single-center randomized trials to multicenter registries following thousands of patients on biologic therapy.

Among the randomized evidence was an investigator-blinded trial that randomized 61 obese patients (BMI > 30) with moderate to severe plaque psoriasis to cyclosporine 2.5 mg/kg/day with or without a low-calorie diet; at 24 weeks, the diet group had lost an average (SD) of 7.0% (3.5%) of body weight and 66.7% achieved PASI 75, vs 29.0% of patients on cyclosporine alone (P < .001). A 2019 Cochrane review reached a similar conclusion from the opposite direction, finding that strict caloric restriction improved patients' likelihood of reaching PASI 75 by roughly two-thirds (relative risk, 1.66; 95% CI, 1.07-2.58) and probably improved quality of life as well.

Fixed-Dose Biologics Lose Ground in Obese Patients

Across drug classes, higher body weight was tied to lower serum drug concentrations, reduced PASI90 and PASI100 response, and higher discontinuation among fixed-dose biologics such as anti-tumor necrosis factor and anti-IL-17 agents. The effect was heterogeneous: some cohorts found obesity had little bearing on long-term adalimumab or brodalumab effectiveness, while others linked higher BMI to blunted response to secukinumab, ixekizumab, guselkumab, and risankizumab on the most stringent clearance endpoints.

Weight-based dosing partly closed that gap. Ustekinumab carries a label-directed 90-mg dose above a 100-kg threshold, and tildrakizumab's 200-mg dose, approved above 90 kg, outperformed the 100-mg dose in higher-weight groups with similar safety. Infliximab's per-kilogram dosing showed comparable short-term efficacy across BMI categories in trial subgroups, though real-world dosing can drift below target in severe obesity. Bimekizumab and brodalumab, by contrast, sustained high rates of clearance across BMI strata in both trial and real-world analyses.

Weight Loss, and Possibly GLP-1 Drugs, as Adjunctive Therapy

The review positioned weight reduction as a therapeutic lever, not merely a risk factor. Bariatric surgery series have reported substantial improvement or remission of psoriasis after major weight loss, an effect attributed to reduced systemic inflammation, normalized adipokine levels, and decreased mechanical stress on skin folds.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs)—including liraglutide, semaglutide, and the dual agonist tirzepatide—emerged as an early-stage adjunctive option, with mechanistic and small cohort studies suggesting they lower psoriasis severity through weight loss and direct anti-inflammatory effects on cytokine production and immune cell activity. One 2025 publication cited in the review proposed tirzepatide as an add-on for obese patients already receiving biologic therapy. “Integrated, multidisciplinary management strategies combining effective anti-psoriatic therapy with weight reduction and cardiometabolic risk control represent the cornerstone of modern psoriasis care,” the authors wrote.

Evidence Gaps Remain Around Newer Agents

The review acknowledged real limits to the evidence. It is a narrative rather than a systematic review, and much of the obesity-response data came from heterogeneous, often retrospective, real-world cohorts rather than trials designed to test BMI as a primary variable. No randomized trials support escalating IL-17 inhibitor doses beyond labeled schedules in obese patients, and no large randomized trials or meta-analyses have directly compared GLP-1RAs against standard psoriasis therapies.

For clinicians and payers alike, the takeaway was practical. BMI and weight history belong in the treatment-selection conversation alongside disease severity, and a patient who plateaus on a fixed-dose biologic may benefit from a weight-based option, a class switch, or structured weight management rather than an assumption that the drug itself has failed.

References

1. Almeida-Silva G, Antunes J, Ferreira J, Filipe P. Psoriasis in obese patients: pathophysiological interactions, clinical consequences, and therapeutic implications. J Clin Med. 2026;15:4302. doi:10.3390/jcm15114302
2. Wang J, Yu Y, Liu L, et al. Global prevalence of obesity in patients with psoriasis: an analysis in the past two decades. Autoimmun Rev. 2024;23(6):103577. doi:10.1016/j.autrev.2024.103577